Data +Oct 23, 2026
Positive data — Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improve…▸
high impact
ReadoutOct 01, 2026
Clinical data — Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrati…▸
medium impact
ReadoutSep 30, 2026
Clinical data — Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90…▸
medium impact
DealSep 29, 2026
Deal — Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After…▸
medium impact
FilingSep 17, 2026
Regulatory filing — Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?▸
medium impact
ReadoutSep 14, 2026
Clinical data — Takeda's Zasocitinib Shows About 70% Of Patients Achieving Clear Or Almost Clear Skin At Week 16 In Phase 3 LATITUDE Ps…▸
medium impact
FilingSep 14, 2026
Regulatory filing — U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psori…▸
medium impact
ApprovalSep 01, 2026
FDA approval — The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones▸
high impact
ApprovalAug 31, 2026
FDA approval — Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug▸
high impact
ApprovalAug 28, 2026
FDA approval — Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Pol…▸
high impact
ApprovalAug 06, 2026
FDA approval — Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval▸
high impact
ApprovalAug 05, 2026
FDA approval — U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcol…▸
high impact
FilingJul 31, 2026
Regulatory filing — Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate▸
medium impact
DealJul 30, 2026
Deal — Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda▸
medium impact
ReadoutJul 27, 2026
Clinical data — How New Phase 3 Psoriasis Data For Zasocitinib At Takeda Pharmaceutical (TSE:4502) Has Changed Its Investment Story▸
medium impact
EarningsJun 17, 2026
FY 2026 report+2.7%muted
EarningsJun 25, 2025
FY 2025 report+3.3%positive